Legislation governing pluripotent stem cells in South Africa

One of the most exciting areas of medical research involves the use of stem cells for the treatment of patients with a variety of diseases and for tissue repair. Although stem cell research is accelerating rapidly in many countries, it has in the past been limited in South Africa (SA); very little h...

Full description

Bibliographic Details
Main Authors: Michael Pepper, C Gouveia, M Slabbert
Format: Article
Language:English
Published: South African Medical Association 2015-09-01
Series:South African Journal of Bioethics and Law
Online Access:http://www.sajbl.org.za/index.php/sajbl/article/download/418/411
_version_ 1797331503483453440
author Michael Pepper
C Gouveia
M Slabbert
author_facet Michael Pepper
C Gouveia
M Slabbert
author_sort Michael Pepper
collection DOAJ
description One of the most exciting areas of medical research involves the use of stem cells for the treatment of patients with a variety of diseases and for tissue repair. Although stem cell research is accelerating rapidly in many countries, it has in the past been limited in South Africa (SA); very little has been done in this country to explore the great potential offered by stem cells to address the high disease burden. Stem cell therapy has however been practised for many years, in SA and worldwide, in the form of haematopoietic stem cell transplantation, mainly for haematological malignancies. From a therapeutic perspective, two types of stem cells can be defined: pluripotent stem cells and adult stem cells. Pluripotent cells derived from the inner cell mass of blastocysts (either from in vitro fertilisation or following somatic cell nuclear transfer) are called embryonic stem (ES) cells, while those derived by reprogramming adult cells are called induced pluripotent stem (iPS) cells. Adult stem cells include haematopoietic, mesenchymal and neural stem cells.The purpose of this article is to critically examine the SA legislation with regard to elements that impact on pluripotent stem cell research and the use of pluripotent stem cells for therapeutic purposes. This includes (but is not limited to) legislation from the National Health Act (Chapter 8 in particular) and its regulations, and deals with matters related to research on embryos in the stem cell context, somatic cell nuclear transfer, reproductive and therapeutic cloning and the generation and therapeutic use of iPS and ES cells.
first_indexed 2024-03-08T07:36:30Z
format Article
id doaj.art-bd3450faff284bdbb34c96b14e49eb20
institution Directory Open Access Journal
issn 1999-7639
language English
last_indexed 2024-03-08T07:36:30Z
publishDate 2015-09-01
publisher South African Medical Association
record_format Article
series South African Journal of Bioethics and Law
spelling doaj.art-bd3450faff284bdbb34c96b14e49eb202024-02-02T18:52:39ZengSouth African Medical AssociationSouth African Journal of Bioethics and Law1999-76392015-09-0182232310.7196/SAJBL.8402Legislation governing pluripotent stem cells in South AfricaMichael PepperC GouveiaM SlabbertOne of the most exciting areas of medical research involves the use of stem cells for the treatment of patients with a variety of diseases and for tissue repair. Although stem cell research is accelerating rapidly in many countries, it has in the past been limited in South Africa (SA); very little has been done in this country to explore the great potential offered by stem cells to address the high disease burden. Stem cell therapy has however been practised for many years, in SA and worldwide, in the form of haematopoietic stem cell transplantation, mainly for haematological malignancies. From a therapeutic perspective, two types of stem cells can be defined: pluripotent stem cells and adult stem cells. Pluripotent cells derived from the inner cell mass of blastocysts (either from in vitro fertilisation or following somatic cell nuclear transfer) are called embryonic stem (ES) cells, while those derived by reprogramming adult cells are called induced pluripotent stem (iPS) cells. Adult stem cells include haematopoietic, mesenchymal and neural stem cells.The purpose of this article is to critically examine the SA legislation with regard to elements that impact on pluripotent stem cell research and the use of pluripotent stem cells for therapeutic purposes. This includes (but is not limited to) legislation from the National Health Act (Chapter 8 in particular) and its regulations, and deals with matters related to research on embryos in the stem cell context, somatic cell nuclear transfer, reproductive and therapeutic cloning and the generation and therapeutic use of iPS and ES cells.http://www.sajbl.org.za/index.php/sajbl/article/download/418/411
spellingShingle Michael Pepper
C Gouveia
M Slabbert
Legislation governing pluripotent stem cells in South Africa
South African Journal of Bioethics and Law
title Legislation governing pluripotent stem cells in South Africa
title_full Legislation governing pluripotent stem cells in South Africa
title_fullStr Legislation governing pluripotent stem cells in South Africa
title_full_unstemmed Legislation governing pluripotent stem cells in South Africa
title_short Legislation governing pluripotent stem cells in South Africa
title_sort legislation governing pluripotent stem cells in south africa
url http://www.sajbl.org.za/index.php/sajbl/article/download/418/411
work_keys_str_mv AT michaelpepper legislationgoverningpluripotentstemcellsinsouthafrica
AT cgouveia legislationgoverningpluripotentstemcellsinsouthafrica
AT mslabbert legislationgoverningpluripotentstemcellsinsouthafrica